Related Experiment Video
Updated: Mar 31, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Companion diagnostics for the targeted therapy of gastric cancer
Changhoon Yoo1, Young Soo Park1
1Changhoon Yoo, Departments of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, South Korea.
Abstract:
Gastric cancer is the fourth most common type of cancer and represents a major cause of cancer-related deaths worldwide. With recent biomedical advances in our understanding of the molecular characteristics of gastric cancer, many genetic alterations have been identified as potential targets for its treatment. Multiple novel agents are currently under development as the demand for active agents that improve the survival of gastric cancer patients constantly increases. Based on lessons from previous trials of targeted agents, it is now widely accepted that the establishment of an optimal diagnostic test to select molecularly defined patients is of equal importance to the development of active agents against targetable genetic alterations. Herein, we highlight the current status and future perspectives of companion diagnostics in the treatment of gastric cancer.
Insights
Companion diagnostics are crucial for developing targeted gastric cancer treatments. These tests identify patients with specific genetic alterations, improving treatment efficacy and patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gastric cancer is a leading cause of cancer deaths globally.
- Advances in understanding molecular characteristics have identified genetic targets for treatment.
- Novel therapeutic agents for gastric cancer are under development.
Purpose of the Study:
- To review the current landscape of companion diagnostics in gastric cancer treatment.
- To discuss future directions for companion diagnostics in this field.
Main Methods:
- Literature review of recent advances in gastric cancer molecular profiling.
- Analysis of the role of companion diagnostics in targeted therapy development.
- Exploration of clinical trial data and future research trends.
Main Results:
- Identification of numerous genetic alterations as potential therapeutic targets in gastric cancer.
- Recognition of the critical role of companion diagnostics in patient selection for targeted therapies.
- Emerging novel agents necessitate companion diagnostics for optimal use.
Conclusions:
- Companion diagnostics are essential for the successful implementation of targeted therapies in gastric cancer.
- The development of effective diagnostic tests is as vital as the development of novel therapeutic agents.
- Future research should focus on refining companion diagnostics to personalize gastric cancer treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies